BMI View: We expect poor economic conditions in Morocco will lead to continuing decline in
pharmaceutical imports and spending in the short term. However, the rate of decline in pharmaceutical
sales is starting to slow, indicating that conditions for Moroccan drugmake ..."
BMI View: We expect the contraction in pharmaceutical spending in Morocco to continue in the short term
as the government seeks to reduce the country's large fiscal deficit and multiple strains on household
incomes weaken domestic demand. This is combined with access ..."
BMI View: Despite the authorities' focus on expanding healthcare insurance and coverage, risks to such programmes continue to be posed by medical staff shortages as well as by poor allocation of existing capital. Inefficient allocation of resources and funds in government healthc ..."
BMI View: We remain broadly optimistic about the performance of Morocco's pharmaceutical market over
the coming years. The roll-out of the country's compulsory healthcare scheme will support volume
consumption, with values to increase in line with wider economic improvements an ..."
BMI View: While Morocco's pharmaceutical market is small in absolute terms, its forward growth trajectory is encouraging. Positive drivers include population growth and changing epidemiological profile, as well as the authorities' efforts to improve healthcare coverage and servic ..."
Morocco's subsidised health insurance scheme,Régime d'Assistance Médicale (RAMED),launched in March 2012,is experiencing early-stage difficulties with its target to increasehealthcare accessibilityto those on low incomes. This is to be expected, given the evidence of bribery and ..."